Gilead Sciences (Nasdaq: GILD) and Belgium-based Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) have completed the joint acquisition of Ouro Medicines in a deal valued at up to USD 2.175 billion. The transaction centers on gamgertamig (OM336; CM-336), a clinical-stage BCMAxCD3 bispecific T cell engager under development for auto-immune diseaes, originally licensed from China’s Keymed Biosciences. Gilead is taking commercial rights to the molecule outside Greater China, while Lakefront as

The company is expecting to spend $150 million to develop its Wnt/β-catenin pathway inhibitor zolucatetide for desmoid tumors. Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. The Massachusetts biotech, formerly known as FogPharma, announced plans last month to list on the Nasdaq, and has now put some figures behind that ambition. Parabilis reckons it can offer 25 million shares pr

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing. The Series A financing will support comp

June 2, 2026 -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will be used to advance Tavo's pipeline of innovative therapies targeting glaucoma and retinal disease. In conjunction with the financing, Tavo Biotherapeutics also announced the appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer, t

Anthropic has raised $65 billion in Series H funding, bringing its post-money valuation to $965 billion and surpassing OpenAI to become the world's highest-valued private AI company. Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, D1 Capital Partners, GIC, ICONIQ and XN co-led the round. Other investors in the round include AMP PBC, Baillie Gifford, Blackstone, Brookfield, D.E. Shaw Ventures, DST Global, Fidelity Management & Research Company, General Catalyst,

Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years May 28, 2026 -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a definitive financing agreement with an institutional investor providing for

May 27, 2026 -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million. In this private pla

Grant marks Alveo's entry into vaccine manufacturing market, extending its molecular detection platform beyond infectious disease diagnostics. May 26, 2026 -- Alveo Technologies, Inc. (Alveo), a leader in portable molecular sensing solutions, today announced it has been awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore how its platform, already in use around the globe for pathogen detection, can be used in vaccine manufacturing. The award marks Alveo's e

Strengthening balance sheet on path to Nasdaq uplisting May 22, 2026 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggr

Sartorius, a life sciences equipment and services company headquartered in Göttingen, Germany, has opened a new competence center in Freiburg, Germany, dedicated to the development and production of quality-critical materials for the cell and gene therapy market, including cytokines and growth factors. The facility covers approximately 18,000 square meters — roughly 194,000 square feet — and can accommodate up to 180 employees, according to the announcement. The site meets GMP quality standards